Get the Stockscreener App
5.23
3.16%
0.16
Aldeyra Therapeutics Inc stock is traded at $5.23, with a volume of 639.68K.
It is up +3.16% in the last 24 hours and down -8.89% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$5.07
Open:
$5.07
24h Volume:
639.68K
Relative Volume:
0.83
Market Cap:
$313.25M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-6.9733
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
+0.00%
1M Performance:
-8.89%
6M Performance:
+86.12%
1Y Performance:
-2.43%
1-Day Range:
$5.04
$5.24
1-Week Range:
$4.696
$5.35
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.23 | 304.43M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Analyzing net buyer seller activity in Aldeyra Therapeutics Inc.Portfolio Gains Summary & Safe Entry Zone Identification - newser.com
Sentiment analysis tools applied to Aldeyra Therapeutics Inc.Weekly Risk Report & Target Return Focused Picks - newser.com
Published on: 2025-11-03 21:46:12 - newser.com
Aldeyra’s Experimental Drug Shows Promising Results In Mid-Stage Alcohol Hepatitis Trial - MSN
Applying Wyckoff theory to Aldeyra Therapeutics Inc. stockWeekly Loss Report & Weekly High Return Stock Forecasts - newser.com
How to interpret RSI for Aldeyra Therapeutics Inc. stockQuarterly Trade Summary & Capital Efficiency Focused Ideas - newser.com
Smart tools for monitoring Aldeyra Therapeutics Inc.’s price actionJuly 2025 Macro Moves & AI Enhanced Trading Signals - newser.com
Can a trend reversal in Aldeyra Therapeutics Inc. lead to recoveryPortfolio Growth Summary & Daily Technical Stock Forecast Reports - newser.com
Is Aldeyra Therapeutics Inc. stock resilient to inflationWeekly Market Outlook & Technical Confirmation Trade Alerts - newser.com
How Aldeyra Therapeutics Inc. stock performs in weak economyJuly 2025 Intraday Action & Community Consensus Trade Alerts - newser.com
Intraday pattern recognizer results for Aldeyra Therapeutics Inc.2025 Top Decliners & Growth Focused Stock Reports - newser.com
Live market analysis of Aldeyra Therapeutics Inc.2025 Price Momentum & Short-Term Swing Trade Alerts - newser.com
Will Aldeyra Therapeutics Inc. stock split again soonShort Setup & Smart Money Movement Alerts - newser.com
Why Aldeyra Therapeutics Inc. stock could see breakout soonJuly 2025 Market Mood & Breakout Confirmation Alerts - newser.com
Why analysts upgrade Aldeyra Therapeutics Inc. stockJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - newser.com
Automated trading signals detected on Aldeyra Therapeutics Inc.Market Trend Review & Free Reliable Trade Execution Plans - newser.com
Combining price and volume data for Aldeyra Therapeutics Inc.Stock Surge & Safe Capital Allocation Plans - newser.com
Is Aldeyra Therapeutics Inc. stock attractive for ETFsIndex Update & Weekly High Momentum Picks - newser.com
Understanding Aldeyra Therapeutics Inc.’s price movementTrade Entry Report & Reliable Price Action Trade Plans - newser.com
Aldeyra Therapeutics Inc.’s volatility index tracking explainedWeekly Trade Analysis & Consistent Growth Stock Picks - newser.com
Is Aldeyra Therapeutics Inc. stock affected by interest rate hikes2025 EndofYear Setup & AI Enhanced Execution Alerts - newser.com
What insider trading reveals about Aldeyra Therapeutics Inc. stock2025 Momentum Check & High Win Rate Trade Alerts - newser.com
Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success - Indian Pharma Post
Is Aldeyra Therapeutics Inc. stock dividend yield sustainableJuly 2025 Review & AI Enhanced Trade Execution Alerts - newser.com
Catalyst Monitor Outlook, Q4 2025 Report: Pipeline Advances with Key Approvals and Trials: Featuring Cytokinetics's Aficamten, Aldeyra's Reproxalap, GSK's Depemokimab - Yahoo Finance
Evaluating Aldeyra Therapeutics Inc. with trendline analysisWeekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com
Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):